PAREXEL board approves stock repurchase program

Published on August 9, 2012 at 12:32 AM · No Comments

PAREXEL International Corporation (Nasdaq: PRXL) announced today that its Board of Directors has approved a stock repurchase program authorizing the repurchase of up to $200 million of the Company's common stock, subject to the consent of the Company's lenders.  There is no set expiration date for the program. 

The Company intends to use cash on hand, cash generated from operations, existing credit facilities, or other financing to fund the share repurchase program.  As of June 30, 2012, the Company had cash and cash equivalents of approximately $214 million, and availability under its existing lines of credit of $175 million. 

The program does not obligate the Company to acquire any particular amount of common stock, and it could be modified, extended, suspended or discontinued at any time. 

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
(optional)
Post